Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress
Rhea-AI Summary
Climb Bio (Nasdaq: CLYM) announced it will present new clinical data from its budoprutug program at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden, held June 11-14, 2026.
The poster will share safety, B-cell depletion and initial platelet data from the low-dose 250 mg cohort at 24 weeks in an ongoing Phase 1b/2a trial in adults with primary immune thrombocytopenia (ITP).
Positive
- None.
Negative
- None.
News Market Reaction – CLYM
In the May 14 session, CLYM declined 0.70%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Clinical trial Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 07 | Fast Track designation | Positive | +1.9% | FDA Fast Track for budoprutug in pMN with strong Phase 1b outcomes. |
| Sep 29 | Preclinical data update | Positive | -6.6% | Promising CLYM116 preclinical IgAN data showing longer half-life and deeper IgA reduction. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Clinical and preclinical updates have produced mixed reactions, with one positive and one negative move around similar trial news.
Over recent quarters, Climb Bio has highlighted steady progress across its clinical pipeline. Prior clinical-trial news included FDA Fast Track Designation for budoprutug in pMN with strong Phase 1b responses, and promising preclinical data for CLYM116 in IgA nephropathy showing deeper IgA reduction and favorable pharmacokinetics. Those updates produced both positive (+1.93%) and negative (-6.57%) single-day moves. Today’s EHA 2026 presentation announcement fits this ongoing cadence of data-driven clinical communications.
Key Terms
phase 1b/2a medical
monoclonal antibody medical
immune thrombocytopenia medical
b-cell depletion medical
low-fucosylated medical
poster session technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
WELLESLEY HILLS, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced an upcoming presentation on its budoprutug program at the European Hematology Association (EHA) 2026 Congress, which will be held in Stockholm, Sweden June 11-14, 2026.
Climb Bio will present data, including safety, B-cell depletion and initial platelet data from the low dose cohort (250mg at 24 weeks), from the ongoing Phase 1b/2a trial of budoprutug, a novel anti-CD19 monoclonal antibody, in previously treated patients with primary immune thrombocytopenia (ITP).
Abstracts are available on the EHA 2026 website here.
Poster Details
Title: Budoprutug, a Low-Fucosylated Anti-CD19 Monoclonal Antibody, in Adults With Primary Immune Thrombocytopenia: Initial Phase 1b Study Results
Session: Poster Session 2
Poster Number: PS2440
Date / Time: June 13, 2026; 18:45-19:45 CEST
About Climb Bio, Inc.
Climb Bio, Inc. is a clinical-stage biotechnology company with a mission to deliver high impact, disease-modifying medicines for individuals living with immune-mediated diseases, including those affecting kidney health. The Company’s pipeline includes, budoprutug, an anti-CD19 monoclonal antibody that has potential to treat a broad range of B-cell mediated diseases, and CLYM116, an anti-APRIL monoclonal antibody being developed for IgA nephropathy. For more information, please visit climbbio.com.
About Budoprutug
Budoprutug is a clinical-stage, anti-CD19 monoclonal antibody with the potential to address a broad range of B-cell mediated, immune-driven diseases. Designed with enhanced effector function and low picomolar affinity, budoprutug targets and depletes CD19-expressing B cells, including plasmablasts and certain plasma cells, key sources of pathogenic autoantibodies. Early clinical data suggest budoprutug may offer durable B-cell depletion, rapid reductions in autoantibodies, and clinical remission in primary membranous nephropathy (pMN). Budoprutug is being evaluated in clinical trials for pMN, immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE). A subcutaneous formulation is also in development to enable broader patient access. Budoprutug has been granted Orphan Drug Designation and Fast Track Designation by the FDA for the treatment of pMN.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding: future expectations, plans and prospects for Climb Bio; expectations regarding the therapeutic benefits, clinical potential and clinical development of budoprutug; the anticipated timelines for announcing data from Climb Bio’s ongoing and planned clinical trials; plans for the development strategy for budoprutug in immune thrombocytopenia; potential commercial opportunity for budoprutug in immune thrombocytopenia; the sufficiency of Climb Bio’s cash resources for the period anticipated; and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “suggest,” “target,” “would,” “will,” “working” and similar expressions. Forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. Climb Bio may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. These risks and uncertainties include, but are not limited to, important risks and uncertainties associated with: the ability of Climb Bio to timely and successfully achieve or recognize the anticipated benefits of its acquisition of Tenet Medicines, Inc. and its technology transfer and exclusive license agreement with Beijing Mabworks Biotech Co., Ltd.; Climb Bio’s ability to advance budoprutug and CLYM116 on the timelines expected or at all and to obtain and maintain necessary approvals from the U.S. Food and Drug Administration and other regulatory authorities; obtaining and maintaining the necessary approvals from investigational review boards at clinical trial sites and independent data safety monitoring boards; replicating in clinical trials positive results found in early-stage clinical trials or nonclinical studies; competing successfully with other companies that are seeking to develop treatments for primary membranous nephropathy, immune thrombocytopenia, systemic lupus erythematosus, IgA nephropathy and other immune-mediated diseases; maintaining or protecting intellectual property rights related to budoprutug, CLYM116 and/or its other product candidates; managing expenses; changes in applicable laws or regulation; the possibility that Climb Bio may be adversely affected by other economic, business and/or competitive factors; and raising the substantial additional capital needed, on the timeline necessary, to continue development of budoprutug, CLYM116 and any other product candidates Climb Bio may develop. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Climb Bio’s actual results to differ materially from those contained in the forward-looking statements, see the “Risk Factors” section, as well as discussions of potential risks, uncertainties and other important factors, in Climb Bio’s most recent filings with the U.S. Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Climb Bio’s views as of the date hereof and should not be relied upon as representing Climb Bio’s views as of any date subsequent to the date hereof. Climb Bio anticipates that subsequent events and developments will cause Climb Bio’s views to change. However, while Climb Bio may elect to update these forward-looking statements at some point in the future, Climb Bio specifically disclaims any obligation to do so, except as required by law.
Investors and Media
Carlo Tanzi, Ph.D.
Kendall Investor Relations
ctanzi@kendallir.com
